NAVIDEA BIOPHARMACEUTICALS I (NAVB) Forecast, Price Target & Analyst Ratings

NYSEARCA:NAVB • US63937X2027

Current stock price

0.0779 USD
0 (-2.99%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NAVIDEA BIOPHARMACEUTICALS I (NAVB).

Forecast Snapshot

Consensus Price Target

Price Target
$5.10
+ 6,446.85% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Nov 13, 2023
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.86%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$5.10
Upside
+ 6,446.85%
From current price of $0.08 to mean target of $5.10, Based on 7 analyst forecasts
Low
$5.05
Median
$5.10
High
$5.25

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

7 Wall Street analysts provided a forecast for the next 12 months for NAVB. The average price target is 5.1 USD. This implies a price increase of 6446.85% is expected in the next year compared to the current price of 0.0779.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

NAVB Current Analyst RatingNAVB Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

NAVB Historical Analyst RatingsNAVB Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.86%
NAVB was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about NAVB.
In the previous month the buy percentage consensus was at a similar level.
NAVB was analyzed by 7 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release Date
Nov 13, 2023

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2020 2021 2022
Revenue
YoY % growth
NAVB revenue by date.NAVB revenue by date.
915.01K
39.10%		531.51K
-41.91%		65.65K
-87.65%
EBITDA
YoY % growth
NAVB ebitda by date.NAVB ebitda by date.
-10.641M
1.64%		-11.983M
-12.62%		-13.955M
-16.45%
EBIT
YoY % growth
NAVB ebit by date.NAVB ebit by date.
-10.711M
2.29%		-12.06M
-12.60%		-14.051M
-16.50%
Operating Margin
NAVB operating margin by date.NAVB operating margin by date.
-1,170.61%-2,269.09%-21,402.74%
EPS
YoY % growth
NAVB eps by date.NAVB eps by date.
-0.48
40.00%		-0.40
16.67%		N/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

NAVB Yearly Revenue VS EstimatesNAVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M
NAVB Yearly EPS VS EstimatesNAVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2019 2020 2021 -1 -2 -3

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

NAVIDEA BIOPHARMACEUTICALS I / NAVB Forecast FAQ

Can you provide the average price target for NAVIDEA BIOPHARMACEUTICALS I stock?

7 analysts have analysed NAVB and the average price target is 5.1 USD. This implies a price increase of 6446.85% is expected in the next year compared to the current price of 0.0779.

When does NAVIDEA BIOPHARMACEUTICALS I (NAVB) report earnings?

NAVIDEA BIOPHARMACEUTICALS I (NAVB) will report earnings on 2023-11-13, after the market close.

How many analysts have analysed NAVIDEA BIOPHARMACEUTICALS I (NAVB)?

The number of analysts covering NAVIDEA BIOPHARMACEUTICALS I (NAVB) is 7.